

# EXHIBIT L

## QUESTIONNAIRE FOR FILING PROPOSED RULES AND REGULATIONS WITH THE ARKANSAS LEGISLATIVE COUNCIL AND JOINT INTERIM COMMITTEE

DEPARTMENT/AGENCY Department of Human Services  
DIVISION Division of Medical Services  
DIVISION DIRECTOR Dawn Stehle  
CONTACT PERSON Seth Blomeley  
ADDRESS P.O. Box 1437, Slot S295, Little Rock, AR 72203  
PHONE NO. 501-320-6425 FAX NO. 501-404-4619 E-MAIL seth.blomeley@dhs.arkansas.gov  
NAME OF PRESENTER AT COMMITTEE MEETING Tami Harlan  
PRESENTER E-MAIL tami.harlan@dhs.arkansas.gov

### INSTRUCTIONS

- A. Please make copies of this form for future use.
- B. Please answer each question completely using layman terms. You may use additional sheets, if necessary.
- C. If you have a method of indexing your rules, please give the proposed citation after "Short Title of this Rule" below.
- D. Submit two (2) copies of this questionnaire and financial impact statement attached to the front of two (2) copies of the proposed rule and required documents. Mail or deliver to:

**Donna K. Davis**  
**Administrative Rules Review Section**  
**Arkansas Legislative Council**  
**Bureau of Legislative Research**  
**One Capitol Mall, 5<sup>th</sup> Floor**  
**Little Rock, AR 72201**

\*\*\*\*\*

1. What is the short title of this rule? Episode of Care 4-16
2. What is the subject of the proposed rule? To add Urinary Tract Infection Episode of Care to both the Episodes of Care Medicaid manual and the Arkansas State Plan.
3. Is this rule required to comply with a federal statute, rule, or regulation? Yes  No   
If yes, please provide the federal rule, regulation, and/or statute citation. \_\_\_\_\_
4. Was this rule filed under the emergency provisions of the Administrative Procedure Act? Yes  No   
If yes, what is the effective date of the emergency rule? \_\_\_\_\_

When does the emergency rule expire? \_\_\_\_\_

Will this emergency rule be promulgated under the permanent provisions of the Administrative Procedure Act? Yes  No

5. Is this a new rule? Yes  No   
If yes, please provide a brief summary explaining the regulation. \_\_\_\_\_

Does this repeal an existing rule? Yes  No   
If yes, a copy of the repealed rule is to be included with your completed questionnaire. If it is being replaced with a new rule, please provide a summary of the rule giving an explanation of what the rule does. \_\_\_\_\_

Is this an amendment to an existing rule? Yes  No   
If yes, please attach a mark-up showing the changes in the existing rule and a summary of the substantive changes. **Note: The summary should explain what the amendment does, and the mark-up copy should be clearly labeled "mark-up."**

6. Cite the state law that grants the authority for this proposed rule? If codified, please give the Arkansas Code citation. Arkansas Statute 20-76-201

7. What is the purpose of this proposed rule? Why is it necessary? The purpose of the proposed rule is to add Urinary Tract Infection Episodes of Care to both the Episodes of Care Medicaid manual and the Arkansas State Plan. Medicaid established a payment improvement initiative to incentivize improved care quality, efficiency and economy. The program uses Medicaid paid claims data to evaluate the quality, efficiency and economy of care delivered in the course of the episode, and to apply payment incentives. The proposed rule is necessary to inform Arkansas Medicaid providers of the Arkansas Medicaid requirements for Urinary Tract Infection episodes.

8. Please provide the address where this rule is publicly accessible in electronic form via the Internet as required by Arkansas Code § 25-19-108(b).  
<https://www.medicaid.state.ar.us/general/comment/comment.aspx>

9. Will a public hearing be held on this proposed rule? Yes  No

If yes, please complete the following:  
Date: July 11, 2016  
Time: 5:30 pm - 7:00 pm  
Central Arkansas Library  
Darragh Center Auditorium  
100 Rock Street  
Place: Little Rock, AR 72201

10. When does the public comment period expire for permanent promulgation? (Must provide a date.)  
July 26, 2016

11. What is the proposed effective date of this proposed rule? (Must provide a date.)  
October 1, 2016

12. Do you expect this rule to be controversial? Yes  No

While the Medicaid paid claims-based payment improvement initiative does not change current reimbursement processes, there is a risk that providers could incur a negative incentive payment that would require them to remit money back to Arkansas Medicaid.

If yes, please explain.

13. Please give the names of persons, groups, or organizations that you expect to comment on these rules?  
Please provide their position (for or against) if known.  
Medical associations, interested providers and advocacy organizations. Their positions for or against is not known at this time.
-

**FINANCIAL IMPACT STATEMENT**

**PLEASE ANSWER ALL QUESTIONS COMPLETELY**

**DEPARTMENT** Department of Human Services  
**DIVISION** Division of Medical Services  
**PERSON COMPLETING THIS STATEMENT** David Walker  
**TELEPHONE NO.** 320-6335 **FAX NO.** 501-404-4619 **EMAIL:** David.Walker@dhs.arkansas.gov

To comply with Ark. Code Ann. § 25-15-204(e), please complete the following Financial Impact Statement and file two copies with the questionnaire and proposed rules.

**SHORT TITLE OF THIS RULE** Episode of Care 4-16 - Urinary Tract Infection

- 1. Does this proposed, amended, or repealed rule have a financial impact? Yes  No
- 2. Is the rule based on the best reasonably obtainable scientific, technical, economic, or other evidence and information available concerning the need for, consequences of, and alternatives to the rule? Yes  No
- 3. In consideration of the alternatives to this rule, was this rule determined by the agency to be the least costly rule considered? Yes  No

If an agency is proposing a more costly rule, please state the following:

- (a) How the additional benefits of the more costly rule justify its additional cost;  
\_\_\_\_\_
- (b) The reason for adoption of the more costly rule;  
\_\_\_\_\_
- (c) Whether the more costly rule is based on the interests of public health, safety, or welfare, and if so, please explain; and;  
\_\_\_\_\_
- (d) Whether the reason is within the scope of the agency's statutory authority; and if so, please explain.  
\_\_\_\_\_

4. If the purpose of this rule is to implement a federal rule or regulation, please state the following:

- (a) What is the cost to implement the federal rule or regulation?

<b><u>Current Fiscal Year</u></b>	<b><u>Next Fiscal Year</u></b>
General Revenue _____	General Revenue _____
Federal Funds _____	Federal Funds _____
Cash Funds _____	Cash Funds _____
Special Revenue _____	Special Revenue _____

Other (Identify) \_\_\_\_\_

Other (Identify) \_\_\_\_\_

Total \_\_\_\_\_

Total \_\_\_\_\_

(b) What is the additional cost of the state rule?

**Current Fiscal Year**

**Next Fiscal Year**

General Revenue	<u>(\$21,449.86)</u>
Federal Funds	<u>(\$50,577.88)</u>
Cash Funds	_____
Special Revenue	_____
Other (Identify)	_____
<b>Total</b>	<u>(\$72,027.74)</u>

General Revenue	<u>(\$28,121.51)</u>
Federal Funds	<u>(\$66,309.36)</u>
Cash Funds	_____
Special Revenue	_____
Other (Identify)	_____
<b>Total</b>	<u>(\$94,430.87)</u>

5. What is the total estimated cost by fiscal year to any private individual, entity and business subject to the proposed, amended, or repealed rule? Identify the entity(ies) subject to the proposed rule and explain how they are affected.

**Current Fiscal Year**

**Next Fiscal Year**

\$ \_\_\_\_\_

\$ \_\_\_\_\_

6. What is the total estimated cost by fiscal year to state, county, and municipal government to implement this rule? Is this the cost of the program or grant? Please explain how the government is affected.

**Current Fiscal Year**

**Next Fiscal Year**

\$ (21,449.86)

\$ (28,121.51)

7. With respect to the agency's answers to Questions #5 and #6 above, is there a new or increased cost or obligation of at least one hundred thousand dollars (\$100,000) per year to a private individual, private entity, private business, state government, county government, municipal government, or to two (2) or more of those entities combined?

Yes  No

If YES, the agency is required by Ark. Code Ann. § 25-15-204(e)(4) to file written findings at the time of filing the financial impact statement. The written findings shall be filed simultaneously with the financial impact statement and shall include, without limitation, the following:

- (1) a statement of the rule's basis and purpose;
- (2) the problem the agency seeks to address with the proposed rule, including a statement of whether a rule is required by statute;
- (3) a description of the factual evidence that:
  - (a) justifies the agency's need for the proposed rule; and

- (b) describes how the benefits of the rule meet the relevant statutory objectives and justify the rule's costs;
- (4) a list of less costly alternatives to the proposed rule and the reasons why the alternatives do not adequately address the problem to be solved by the proposed rule;
- (5) a list of alternatives to the proposed rule that were suggested as a result of public comment and the reasons why the alternatives do not adequately address the problem to be solved by the proposed rule;
- (6) a statement of whether existing rules have created or contributed to the problem the agency seeks to address with the proposed rule and, if existing rules have created or contributed to the problem, an explanation of why amendment or repeal of the rule creating or contributing to the problem is not a sufficient response; and
- (7) an agency plan for review of the rule no less than every ten (10) years to determine whether, based upon the evidence, there remains a need for the rule including, without limitation, whether:
  - (a) the rule is achieving the statutory objectives;
  - (b) the benefits of the rule continue to justify its costs; and
  - (c) the rule can be amended or repealed to reduce costs while continuing to achieve the statutory objectives.

**SUMMARY OF  
EPISODES OF CARE 4-16 – URINARY TRACT INFECTION**

**Effective October 1, 2016 Arkansas Medicaid proposes to add Urinary Tract Infection episodes to the Episodes of Care Medicaid manual and Arkansas State Plan to incentivize improved care quality, efficiency, and economy. The program uses Medicaid paid claims data to evaluate the quality, efficiency, and economy of care delivered in the course of the episode, and to apply payment incentives.**





**TO:** Arkansas Medicaid Health Care Providers – Episodes of Care  
**EFFECTIVE DATE:** October 1, 2016  
**SUBJECT:** Provider Manual Update Transmittal EPISODE-4-16-UTI

<u>REMOVE</u>		<u>INSERT</u>	
Section	Effective Date	Section	Effective Date
—	—	226.000	10-1-16
—	—	226.100	10-1-16
—	—	226.200	10-1-16
—	—	226.300	10-1-16
—	—	226.400	10-1-16
—	—	226.500	10-1-16
—	—	226.600	10-1-16
—	—	226.700	10-1-16

**PROPOSED**

**Explanation of Updates**

Sections 226.000, 226.100, 226.200, 226.300, 226.400, 226.500, 226.600 and 226.700 are added to provide information pertaining to the urinary tract infection episode of care.


The paper version of this update transmittal includes revised pages that may be filed in your provider manual. See Section I for instructions on updating the paper version of the manual. For electronic versions, these changes have already been incorporated.

If you have questions regarding this transmittal, please contact the Arkansas Payment Improvement Initiative Center at 1-866-322-4696 (Toll-Free) within Arkansas or locally and Out-of-State at (501) 301-8311.

If you need this material in an alternative format, such as large print, please contact the Program Development and Quality Assurance Unit at (501) 320-6429.

Arkansas Medicaid provider manuals (including update transmittals), official notices, notices of rule making and remittance advice (RA) messages are available for downloading from the Arkansas Medicaid website: [www.medicaid.state.ar.us](http://www.medicaid.state.ar.us).

Thank you for your participation in the Arkansas Medicaid Program.

  
Dawn Stehle  
Director

*TOC is required*

## 226.000 URINARY TRACT INFECTION (UTI) EPISODES

226.100 Episode Definition/Scope of Services 10-1-16

A. Episode subtypes:

There are no subtypes for this episode type.

B. Episode trigger:

Episode is triggered by an Emergency Department (ED) visit where the primary diagnosis (Dx1) is related to Urinary Tract Infection (e.g., cystitis, urethritis and pyelonephritis).

C. Episode duration:

Episode begins on the date of admission to the ED and ends 14 days after discharge from ED.

D. Episode services:

The following services are included in the episode:

1. During the trigger event: All diagnostic and treatment services beginning with, and during, the ED admission
2. All cause readmissions from facility discharge day 1 through day 3
3. Relevant complications from day 4 through day 14
4. Within 14 days post-discharge: Related services (i.e., outpatient facility services, professional services, related medications, treatment for complications)

**PROPOSED**

226.200 Principal Accountable Provider 10-1-16

For each episode, the Principal Accountable Provider (PAP) is the facility where the UTI is diagnosed.

226.300 Exclusions 10-1-16

Global Exclusions from Section 200.300 are applied to this episode.

Episode specific exclusions:

- A. Beneficiaries who are less than the age of 6 months or greater than or equal to the age of 65 on the date of the trigger
- B. Beneficiaries with extraordinarily high- or low-cost episodes
- C. Beneficiaries with one or more of the following comorbidities within 365 days prior to the urinary tract infection:
  1. Spina bifida
  2. Coma
  3. Partial or complete paralysis
  4. Tuberculosis of urinary tract
  5. Sexually transmitted infections of the urinary tract
  6. Cerebral palsy

7. Significant urinary tract diseases (e.g., renal abscess, urinary tract calculus, vesicoureteral reflux, hydronephrosis)
8. Bladder dysfunction
9. Multiple sclerosis
10. Beneficiaries aged 4 and over with prescriptions filled for diapers
11. Beneficiaries using catheters
12. Genitourinary Cancer

**226.400 Adjustments 10-1-16**

For the purpose of determining a PAP's performance, the total reimbursement attributable to the PAP is risk-adjusted for urinary tract infection episodes in which patients have comorbidities, including the following related health conditions:

- A. Diabetes
- B. Urinary retention
- C. Pyelonephritis

**PROPOSED**

**226.500 Quality Measures 10-1-16**

- A. Quality measures "to pass":
  1. Percent of valid episodes in which clinically inappropriate antibiotics (Ampicillin, 3rd generation Cephalosporins, Quinolones) are prescribed – must be below maximum threshold of 25%.
- B. Quality measures "to track":
  1. Percent of episodes including a CBC (complete blood count)
  2. Percent of episodes including a urine culture
  3. Rate of abdominal CT Scans

**226.600 Thresholds for Incentive Payments 10-1-16**

- A. The acceptable threshold is \$275.00.
- B. The commendable threshold is \$243.00.
- C. The gain sharing limit is \$117.00.
- D. The gain sharing percentage is 50%.
- E. The risk sharing percentage is 50%.

**226.700 Minimum Case Volume 10-1-16**

The minimum case volume is 5 valid episodes per 12-month performance period.

TOC is required

**226.000 URINARY TRACT INFECTION (UTI) EPISODES****226.100 Episode Definition/Scope of Services 10-1-16****A. Episode subtypes:**

There are no subtypes for this episode type.

**B. Episode trigger:**

Episode is triggered by an Emergency Department (ED) visit where the primary diagnosis (Dx1) is related to Urinary Tract Infection (e.g., cystitis, urethritis and pyelonephritis).

**C. Episode duration:**

Episode begins on the date of admission to the ED and ends 14 days after discharge from ED.

**D. Episode services:**

The following services are included in the episode:

1. During the trigger event: All diagnostic and treatment services beginning with, and during, the ED admission
2. All cause readmissions from facility discharge day 1 through day 3
3. Relevant complications from day 4 through day 14
4. Within 14 days post-discharge: Related services (i.e., outpatient facility services, professional services, related medications, treatment for complications)

**226.200 Principal Accountable Provider 10-1-16**

For each episode, the Principal Accountable Provider (PAP) is the facility where the UTI is diagnosed.

**226.300 Exclusions 10-1-16**

Global Exclusions from Section 200.300 are applied to this episode.

Episode specific exclusions:

- A. Beneficiaries who are less than the age of 6 months or greater than or equal to the age of 65 on the date of the trigger
- B. Beneficiaries with extraordinarily high- or low-cost episodes
- C. Beneficiaries with one or more of the following comorbidities within 365 days prior to the urinary tract infection:
  1. Spina bifida
  2. Coma
  3. Partial or complete paralysis
  4. Tuberculosis of urinary tract
  5. Sexually transmitted infections of the urinary tract
  6. Cerebral palsy

7. Significant urinary tract diseases (e.g., renal abscess, urinary tract calculus, vesicoureteral reflux, hydronephrosis)
8. Bladder dysfunction
9. Multiple sclerosis
10. Beneficiaries aged 4 and over with prescriptions filled for diapers
11. Beneficiaries using catheters
12. Genitourinary Cancer

**226.400 Adjustments****10-1-16**

For the purpose of determining a PAP's performance, the total reimbursement attributable to the PAP is risk-adjusted for urinary tract infection episodes in which patients have comorbidities, including the following related health conditions:

- A. Diabetes
- B. Urinary retention
- C. Pyelonephritis

**226.500 Quality Measures****10-1-16**

- A. Quality measures "to pass":
  1. Percent of valid episodes in which clinically inappropriate antibiotics (Ampicillin, 3rd generation Cephalosporins, Quinolones) are prescribed – must be below maximum threshold of 25%.
- B. Quality measures "to track":
  1. Percent of episodes including a CBC (complete blood count)
  2. Percent of episodes including a urine culture
  3. Rate of abdominal CT Scans

**226.600 Thresholds for Incentive Payments****10-1-16**

- A. The acceptable threshold is \$275.00.
- B. The commendable threshold is \$243.00.
- C. The gain sharing limit is \$117.00.
- D. The gain sharing percentage is 50%.
- E. The risk sharing percentage is 50%.

**226.700 Minimum Case Volume****10-1-16**

The minimum case volume is 5 valid episodes per 12-month performance period.